Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Scheriproct Suppositories

Active Ingredient:
cinchocaine hydrochloride , prednisolone hexanoate
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Product Information
{arrow_left}
{arrow_right}
Product Information – Scheriproct Suppositories change of ownership

Please note that following a Change of Ownership, Karo Pharma are now Marketing Authorisation Holder for Scheriproct Suppositories.

For a period of time you may still receive packs of Scheriproct Suppositories in LEO Laboratories Limited packaging, displaying a LEO Laboratories Limited Marketing Authorisation number.

Please contact Karo Pharma for any queries related to this product.

Email: [email protected]
Tel: 0-808-189-4327
Karo Pharma AB
Company image
Address
Klara Norra Kyrkogata 33, Stockholm, Sweden
WWW
https://www.karopharma.com/
Telephone
+44 (0) 8000461977
Medical Information Direct Line
+44 (0) 8000461977
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0) 8000461977
Stock Availability
[email protected]